Problem

Corveus Medical is addressing chronic heart failure, a condition in which the heart cannot pump enough oxygenated blood to meet the body’s needs. The disease affects more than 64 million people worldwide, and its economic burden is substantial: heart-failure-specific hospitalizations have been estimated to cost roughly $10,737–$17,830 each. Corveus is particularly focused on moderate, symptomatic patients whose needs are not adequately addressed by existing treatments, including class III patients experiencing fluid buildup in the heart and lungs.

The central use case is a patient who remains significantly limited by chronic heart-failure symptoms despite medical therapy, but who may not yet be an obvious candidate for more invasive end-stage interventions. For this group, reducing congestion and symptom severity could improve daily function while potentially lowering the costly cycle of deterioration and hospitalization.

Product / Service

Corveus is developing a one-time, minimally invasive, catheter-based procedure that performs targeted nerve ablation in the upper abdomen. The device is intended to inactivate a specific sympathetic, or splanchnic, nerve branch that drives excess fluid accumulation in the heart and lungs. Its catheter is designed to focus the ablation on a precise area and confirm that the treatment was performed correctly, addressing cardiologists’ concern about collateral tissue damage.

The intended benefit is immediate relief from chronic-heart-failure symptoms and a reduction in disease severity without a permanent implant. The company describes the therapy as an option for patients whose symptoms are not addressed by current solutions, but the evidence places the product in preclinical development rather than routine clinical delivery: Corveus had completed animal studies and was preparing for its first-in-human study.

Market

Corveus competes in cardiovascular medical devices, specifically the emerging heart-failure neuromodulation and catheter-based intervention segment. The broader congestive-heart-failure treatment-device market includes established companies such as GE HealthCare, Boston Scientific, Medtronic, Abbott, Biotronik, and LivaNova. The evidence does not identify a directly equivalent commercial splanchnic-nerve-ablation product; adjacent neuromodulation efforts have included Enopace’s catheter-based neurostimulator and NeuroTronik’s heart-failure device.

Corveus appears pre-revenue and pre-commercial based on the available evidence. It was founded in 2021, entered Y Combinator’s Winter 2022 cohort, was listed as active with a three-person team, joined Fogarty Innovation’s accelerator in 2024, and participated in the Creative Destruction Lab’s 2023/24 biomedical-engineering cohort. The company reported raising just under $1 million after initiating animal studies, while its stated next milestones were additional grants and funding, a first-in-human study, and a path toward commercialization; an available company profile does not report current revenue.